Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer

H. Matzkin, P. Eber, B. Todd, R. Van der Zwaag, M. S. Soloway

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Background. The prognostic value was determined of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) measured before and after endocrine treatment in 57 patients with newly diagnosed Stage D2 prostatic cancer. Methods. Therapy included orchiectomy or administration of luteinizing hormone releasing hormone analogues or an antiandrogen. Results. The absolute pretreatment PSA (elevated in 100% of patients) but not PAP (abnormal in 93%) predicted disease progression (P < 0.0011), i.e., a poor response to therapy. Fifty-three patients responded to androgen deprivation with a decrease in PSA level. This declined to normal at 3 and 6 months in 25% of patients. Forty-nine percent had a greater than 90% decrease in their PSA level. By 1 year, 58% of patients had progressive disease. Both the nadir PSA level and the percent decline from the pretreatment level at 3 and 6 months predicted the progression-free interval (P < 0.001). Patients with a 90% or greater decline in PSA had a prolonged progression-free survival. Serial PAP levels were similarly prognostic. Conclusion. It was concluded that PSA was better than PAP in evaluating patients before and after androgen-deprivation therapy. The nadir level of both markers was an important tool to predict progression-free survival in patients with metastatic prostatic cancer.

Original languageEnglish
Pages (from-to)2302-2309
Number of pages8
JournalCancer
Volume70
Issue number9
DOIs
StatePublished - Oct 30 1992
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostate
Prostatic Neoplasms
Therapeutics
Androgens
Disease-Free Survival
Androgen Antagonists
Orchiectomy
Gonadotropin-Releasing Hormone
Disease Progression
prostatic acid phosphatase

Keywords

  • prognosis
  • prostate-specific antigen
  • prostatic acid phosphatase
  • prostatic neoplasm

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. / Matzkin, H.; Eber, P.; Todd, B.; Van der Zwaag, R.; Soloway, M. S.

In: Cancer, Vol. 70, No. 9, 30.10.1992, p. 2302-2309.

Research output: Contribution to journalArticle

Matzkin, H. ; Eber, P. ; Todd, B. ; Van der Zwaag, R. ; Soloway, M. S. / Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. In: Cancer. 1992 ; Vol. 70, No. 9. pp. 2302-2309.
@article{26afe53235d24000bebe52c0dcd265d8,
title = "Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer",
abstract = "Background. The prognostic value was determined of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) measured before and after endocrine treatment in 57 patients with newly diagnosed Stage D2 prostatic cancer. Methods. Therapy included orchiectomy or administration of luteinizing hormone releasing hormone analogues or an antiandrogen. Results. The absolute pretreatment PSA (elevated in 100{\%} of patients) but not PAP (abnormal in 93{\%}) predicted disease progression (P < 0.0011), i.e., a poor response to therapy. Fifty-three patients responded to androgen deprivation with a decrease in PSA level. This declined to normal at 3 and 6 months in 25{\%} of patients. Forty-nine percent had a greater than 90{\%} decrease in their PSA level. By 1 year, 58{\%} of patients had progressive disease. Both the nadir PSA level and the percent decline from the pretreatment level at 3 and 6 months predicted the progression-free interval (P < 0.001). Patients with a 90{\%} or greater decline in PSA had a prolonged progression-free survival. Serial PAP levels were similarly prognostic. Conclusion. It was concluded that PSA was better than PAP in evaluating patients before and after androgen-deprivation therapy. The nadir level of both markers was an important tool to predict progression-free survival in patients with metastatic prostatic cancer.",
keywords = "prognosis, prostate-specific antigen, prostatic acid phosphatase, prostatic neoplasm",
author = "H. Matzkin and P. Eber and B. Todd and {Van der Zwaag}, R. and Soloway, {M. S.}",
year = "1992",
month = "10",
day = "30",
doi = "10.1002/1097-0142(19921101)70:9<2302::AID-CNCR2820700915>3.0.CO;2-2",
language = "English",
volume = "70",
pages = "2302--2309",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer

AU - Matzkin, H.

AU - Eber, P.

AU - Todd, B.

AU - Van der Zwaag, R.

AU - Soloway, M. S.

PY - 1992/10/30

Y1 - 1992/10/30

N2 - Background. The prognostic value was determined of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) measured before and after endocrine treatment in 57 patients with newly diagnosed Stage D2 prostatic cancer. Methods. Therapy included orchiectomy or administration of luteinizing hormone releasing hormone analogues or an antiandrogen. Results. The absolute pretreatment PSA (elevated in 100% of patients) but not PAP (abnormal in 93%) predicted disease progression (P < 0.0011), i.e., a poor response to therapy. Fifty-three patients responded to androgen deprivation with a decrease in PSA level. This declined to normal at 3 and 6 months in 25% of patients. Forty-nine percent had a greater than 90% decrease in their PSA level. By 1 year, 58% of patients had progressive disease. Both the nadir PSA level and the percent decline from the pretreatment level at 3 and 6 months predicted the progression-free interval (P < 0.001). Patients with a 90% or greater decline in PSA had a prolonged progression-free survival. Serial PAP levels were similarly prognostic. Conclusion. It was concluded that PSA was better than PAP in evaluating patients before and after androgen-deprivation therapy. The nadir level of both markers was an important tool to predict progression-free survival in patients with metastatic prostatic cancer.

AB - Background. The prognostic value was determined of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) measured before and after endocrine treatment in 57 patients with newly diagnosed Stage D2 prostatic cancer. Methods. Therapy included orchiectomy or administration of luteinizing hormone releasing hormone analogues or an antiandrogen. Results. The absolute pretreatment PSA (elevated in 100% of patients) but not PAP (abnormal in 93%) predicted disease progression (P < 0.0011), i.e., a poor response to therapy. Fifty-three patients responded to androgen deprivation with a decrease in PSA level. This declined to normal at 3 and 6 months in 25% of patients. Forty-nine percent had a greater than 90% decrease in their PSA level. By 1 year, 58% of patients had progressive disease. Both the nadir PSA level and the percent decline from the pretreatment level at 3 and 6 months predicted the progression-free interval (P < 0.001). Patients with a 90% or greater decline in PSA had a prolonged progression-free survival. Serial PAP levels were similarly prognostic. Conclusion. It was concluded that PSA was better than PAP in evaluating patients before and after androgen-deprivation therapy. The nadir level of both markers was an important tool to predict progression-free survival in patients with metastatic prostatic cancer.

KW - prognosis

KW - prostate-specific antigen

KW - prostatic acid phosphatase

KW - prostatic neoplasm

UR - http://www.scopus.com/inward/record.url?scp=0026687613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026687613&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19921101)70:9<2302::AID-CNCR2820700915>3.0.CO;2-2

DO - 10.1002/1097-0142(19921101)70:9<2302::AID-CNCR2820700915>3.0.CO;2-2

M3 - Article

VL - 70

SP - 2302

EP - 2309

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -